Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
September 2022
|
| gptkbp:ATCCode |
L03AA15
|
| gptkbp:brand |
gptkb:Rolontis
|
| gptkbp:countryOfOperation |
gptkb:South_Korea
gptkb:United_States |
| gptkbp:form |
injection
|
| gptkbp:genericName |
eflapegrastim
|
| gptkbp:halfLife |
approximately 42 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Rolontis
|
| gptkbp:indication |
reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Spectrum_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
long-acting granulocyte colony-stimulating factor (G-CSF) analog
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
nausea
fatigue headache bone pain |
| gptkbp:status |
FDA approved
|
| gptkbp:bfsParent |
gptkb:Spectrum_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|